Vineet Laboratories
NSE: VINEETLAB · ISIN INE505Y01010 · Basic Materials
₹37.39−0.77 (−2.02%)
Monday 9 November, 11:53 IST. Delayed. Source: Yahoo Finance.
Price chart
This chart is unavailable right now.
The day
- Previous close
- ₹38.16
- Open
- ₹38.80
- Day high
- ₹38.80
- Day low
- ₹36.92
Listed on NSE since 15 June 2021.
Key numbers
- Market value
- ₹71.14 Cr
- P/E (trailing)
- 15.18
- EPS (trailing)
- ₹2.44
- Price to book
- 1.37
- Dividend yield
- 0.00%
- Debt to equity
- 0.99
- Profit margin
- 5.6%
- Beta
- 0.17
- Volume today
- 25,141
- Average volume
- 1.11 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹212.29 Cr | ₹1.25 Cr |
| FY24 | ₹150.59 Cr | ₹1.03 Cr |
| FY25 | ₹75.00 Cr | ₹-20.19 Cr |
| FY26 | ₹59.40 Cr | ₹1.11 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹10 Cr | ₹2 Cr | – |
| Q4 FY26Jan–Mar 2026Audited | ₹19 Cr | ₹1 Cr | – |
| Q3 FY26Oct–Dec 2025 | ₹16 Cr | ₹85.07 L | – |
| Q2 FY26Jul–Sep 2025 | ₹17 Cr | ₹40.10 L | – |
| Q1 FY26Apr–Jun 2025 | ₹7 Cr | ₹-86.61 L | – |
| Q4 FY25Jan–Mar 2025Audited | ₹14 Cr | ₹-11 Cr | – |
Source: Vineet Laboratories’s results filed with NSE, standalone (the company alone). Net profit is the share of Vineet Laboratories’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss. EPS before Q1 FY27 is not shown: the share count changed (a bonus, split or merger), so it would not compare.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | March 2026 | September 2025 |
|---|---|---|
| Fixed assets | ₹24 Cr | ₹24 Cr |
| Investments | ₹19.41 L | ₹21.82 L |
| Inventories | ₹64 Cr | ₹57 Cr |
| Owed by customers | ₹11 Cr | ₹4 Cr |
| Cash and equivalents | ₹17 Cr | ₹28.17 L |
| Total assets | ₹125 Cr | ₹91 Cr |
| Borrowings | ₹45 Cr | ₹43 Cr |
| Total liabilities | ₹79 Cr | ₹76 Cr |
| Shareholders’ equity | ₹46 Cr | ₹14 Cr |
Source: Vineet Laboratories’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.
About Vineet Laboratories
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
- Industry
- Chemicals
- Based in
- Hyderabad
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Vineet Laboratories in the last day or two.
Dividends and corporate actions
All companies- Rights 13:12 @ Premium Rs 20/-
Right · ex-date 23 December 2025
- Annual General Meeting
Action · ex-date 17 September 2024
- Annual General Meeting
Action · ex-date 18 September 2023
- Dividend - Re 1 Per Share
Dividend · ex-date 19 September 2022 · record date 20 September 2022
- Annual General Meeting
Action · ex-date 22 September 2021
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.